Brief: Eloxx Pharmaceuticals Announces Fast Track Designation For Elx-02 For Treatment Of Cystic Fibrosis Patients With Nonsense Mutations

Eloxx Pharmaceuticals

09/09/2021 14:27

Eloxx Pharmaceuticals Inc  ELOX.O :
    * ELOXX PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR
ELX-02 FOR TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH NONSENSE
MUTATIONS
    * ELOXX PHARMACEUTICALS INC - EXPECTS TO PRESENT DATA FROM
FIRST
FOUR TREATMENT ARMS IN Q4 OF 2021

Source text for Eikon:  ID:nGNX5hGkl0 
Further company coverage:  ELOX.O